Expression of microRNA-150 in Peripheral Blood and Its Clinical Significance in Patients with Non-Small Cell Lung Cancer

Xiaoli ZENG,Shaoyan ZHANG,Junfang ZHENG,Yan WANG

DOI: https://doi.org/10.3969/j.issn.1000-8179.2012.22.023

2012-01-01

Chinese Journal of Clinical Oncology

Abstract:Objective:To investigate the expression and clinical significance of miR-150 in non-small cell lung cancer(NSCLC). Methods:Probe-based stem-loop quantitative reverse-transcriptase polymerase chain reaction was used to detect the miR-150 expression in peripheral blood mononuclear cells(PBMC) of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-150 level and clinicopathological factors was explored.Results:miR-150 expressions in PBMC specimens between the cancer patients and the healthy individuals was not significantly different(P=0.260).The miR-150 expression in lung adenocarcinoma patients was significantly higher than that in healthy individuals(P=0.001).miR-150 expressions between the adenocarcinoma and squamous cells in NSCLC showed very strong differences(P=0.000).miR-150 expressions showed low discriminative ROC curve profiles,distinguishing NSCLC patients from healthy subjects by the area under the ROC curve(AUC ) at 0.610(95%CI 0.493 to 0.728 )(P =0.060).High expression of miR-150 was identified as a moderately specific marker for lung adenocarcinoma,distinguishing patients from healthy subjects with AUC at 0.834 (95%CI 0.734 to 0.934 )(P=0.000).Additionally,miR-150 was identified as a highly specific marker for adenocarcinoma distinguished from squamous cell carcinoma in NSCLC with AUC at 0.951(95%CI 0.903 to 0.999 )(P=0.000).The miR-150 level was significantly associated with distant metastasis(P=0.014).No association was found between miR-150 and other clinicopathological features,such as clinical stage and lymphatic metastasis.Conclusion:miR-150 expression in PBMC specimens is significantly increased in lung adenocarcinoma patients.miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma in NSCLC.